Today, Lifecare is pleased to announce that a sensor first used in our ongoing Clinical Development Study has confirmed an operational longevity of 12 weeks in a continued laboratory (in vitro) set up. This is yet another important milestone in the development of our Sencell technology for Continuous Glucose Monitoring (CGM).
The achievement was made possible through the use of a sensor that was first implanted and tested clinically in human (in vivo), and then explanted and transferred to continued testing in vitro. The operational longevity in this combined in vivo and in vitro experiment has passed 12 weeks and is still ongoing.
CEO at Lifecare Joacim Holter
This innovative approach allowed Lifecare to demonstrate the longevity of the Sencell sensor in a more realistic and relevant environment, as well as to document an impressive sensor robustness. The experiment also confirms the stability of the chemistry used in the in the sensor and demonstrates that the technology has a superior longevity compared to existing needle-based CGM sensors.
The 12-week longevity achievement is an important confirmation towards Lifecare’s main goal of achieving a longevity of 6 months or more in vivo for its Sencell sensor. It confirms the potential of the technology to provide long-term and accurate glucose monitoring for people with diabetes, while reducing the need for frequent sensor replacements.
-We are satisfied to tick-off yet another achievement confirming that we are on track with our development to provide a long-term and accurate Continous Glucose Monitor for people with diabetes, Lifecare strive to ensure high quality in all stages of our development, and this ongoing experiment forms an important and reassuring base for our upcoming clinical longevity study, says Joacim Holter, CEO of Lifecare.